JPWO2023141710A5 - - Google Patents
Info
- Publication number
- JPWO2023141710A5 JPWO2023141710A5 JP2024544912A JP2024544912A JPWO2023141710A5 JP WO2023141710 A5 JPWO2023141710 A5 JP WO2023141710A5 JP 2024544912 A JP2024544912 A JP 2024544912A JP 2024544912 A JP2024544912 A JP 2024544912A JP WO2023141710 A5 JPWO2023141710 A5 JP WO2023141710A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- antisense oligonucleotide
- conjugated antisense
- exon
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303577P | 2022-01-27 | 2022-01-27 | |
| US63/303,577 | 2022-01-27 | ||
| PCT/CA2023/050096 WO2023141710A1 (en) | 2022-01-27 | 2023-01-26 | Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508337A JP2025508337A (ja) | 2025-03-26 |
| JP2025508337A5 JP2025508337A5 (https=) | 2026-02-03 |
| JPWO2023141710A5 true JPWO2023141710A5 (https=) | 2026-02-03 |
Family
ID=87469898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544912A Pending JP2025508337A (ja) | 2022-01-27 | 2023-01-26 | 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114464A1 (https=) |
| EP (1) | EP4469576A4 (https=) |
| JP (1) | JP2025508337A (https=) |
| CN (1) | CN119137274A (https=) |
| CA (1) | CA3243078A1 (https=) |
| WO (1) | WO2023141710A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9801948B2 (en) * | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
| US20220288218A1 (en) * | 2019-07-09 | 2022-09-15 | The Governors Of The University Of Alberta | Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene |
| US20230048338A1 (en) * | 2019-12-20 | 2023-02-16 | PYC Therapeutics Limited | Novel cellular delivery methods |
-
2023
- 2023-01-26 US US18/730,955 patent/US20250114464A1/en active Pending
- 2023-01-26 WO PCT/CA2023/050096 patent/WO2023141710A1/en not_active Ceased
- 2023-01-26 JP JP2024544912A patent/JP2025508337A/ja active Pending
- 2023-01-26 CN CN202380028701.3A patent/CN119137274A/zh active Pending
- 2023-01-26 CA CA3243078A patent/CA3243078A1/en active Pending
- 2023-01-26 EP EP23745765.0A patent/EP4469576A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10913946B2 (en) | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy | |
| JP7042255B2 (ja) | ヒトｌｍｎａを標的にするオリゴヌクレオチド類縁体 | |
| JP2023123491A5 (https=) | ||
| EP1416972B1 (en) | Chimeric molecules to modulate gene expression | |
| CA2294988C (en) | Compositions and methods for the delivery of oligonucleotides via the alimentary canal | |
| US6353055B1 (en) | Polynucleotide compositions | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| E Nielsen | Gene targeting and expression modulation by peptide nucleic acids (PNA) | |
| JPWO2023026994A5 (https=) | ||
| CN101448945A (zh) | 用于诱导外显子跳跃的手段和方法 | |
| US20020161209A1 (en) | Compositions inducing cleavage of RNA motifs | |
| JP5674923B2 (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| US20240254464A1 (en) | Cleavage-inactive cas12f1, cleavage-inactive cas12f1-based fusion protein, crispr gene-editing system comprising same, and preparation method and use thereof | |
| JP2004528266A (ja) | 薬物送達用組成物 | |
| JPWO2023141710A5 (https=) | ||
| CN114901823A (zh) | 诱导外显子50的跳读的反义核酸 | |
| JP2019523302A5 (https=) | ||
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| CN118043461A (zh) | 方法 | |
| IL283646B2 (en) | Exon skipping oligomer conjugates for muscular dystrophy | |
| JP7579147B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート | |
| US20040019188A1 (en) | Targeting through integrins | |
| US11898145B2 (en) | Enhanced oligonucleotides for inhibiting RTEL1 expression | |
| JPWO2020123574A5 (https=) | ||
| WO1996035705A1 (en) | Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion |